FedCirc voids Seagen patent in $41m cancer treatment dispute

The appeals court reversed a jury verdict, finding the antibody-drug conjugate patent lacked adequate written description and enablement support from its priority application.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

AbbVie’s trade secret suit against a Chinese rival gets green light

18 May 2026 A US court has refused to throw out AbbVie's claim that a former scientist brought its cancer drug secrets to a Chinese rival.

Americas

WATCH: Kymera Therapeutics’ Sylvia Yip on in-house leadership

18 May 2026 LSIPR’s senior reporter Marisa Woutersen speaks with the director of IP at Kymera Therapeutics about the realities of in-house IP leadership and the growing challenge of “fast followers” in biotech.

Americas

UK govt backs DeepMind spinout’s $2.1bn plan to ‘solve all disease’ with AI

14 May 2026 Isomorphic Labs said the funding round, led by venture firm Thrive Capital, would be used to further its drug design engine and support hiring targets.

More features

AbbVie’s trade secret suit against a Chinese rival gets green light

WATCH: Kymera Therapeutics’ Sylvia Yip on in-house leadership

UK govt backs DeepMind spinout’s $2.1bn plan to ‘solve all disease’ with AI

Blank Rome adds to growing team with patent agent from MBHB

BMS signs $15.2bn deal with China’s top pharma company

Medtech company sues over seven patents for incontinence products

10x Genomics settles suit with rival and targets DNA sequencing startup

Trade secrets, AI and the new scrutiny of big damages awards

FedCirc voids Seagen patent in $41m cancer treatment dispute

More on this story

Editor's picks

Editor's picks

More features